After 12 weeks of lemborexant treatment, of gut microbiota significantly increased in 29 adults with insomnia.
The significantly increased post-treatment.
Seven genera of gut bacteria exhibited significant changes after 12 weeks.
One specific genus decreased significantly and was negatively correlated with sleep efficiency.
Other correlations were observed between gut microbiota and both latency to persistent sleep and sleep efficiency.
Simplified
PURPOSE: Insomnia is a common disorder worldwide. Growing evidence has revealed that the microbiota-gut-brain axis contributes to the regulation of sleep continuity and duration, both directly and indirectly. Although lemborexant is effective in treating insomnia, its effect on the gut microbiota remains unclear. Here, we investigated the relationship between the gut microbiota and hypnotic use in insomnia.
PARTICIPANTS AND METHODS: We enrolled 29 adults with insomnia and performed sleep electroencephalography and stool analyses at baseline and after 4 and 12 weeks of open-label lemborexant treatment. Changes in gut microbiota were analyzed using 16S rRNA sequencing and metabolite analysis was performed to assess short-chain fatty acids (SCFAs).
RESULTS: (Jaccard dissimilarity) and significantly increased after administration of lemborexant for 12 weeks (p < 0.05). Seven genera were significantly different (p < 0.05). Among these,decreased significantly after 12 weeks of lemborexant treatment (p = 0.013), even after correcting for false discovery rates.was strongly negatively correlated with sleep efficiency (r = -0.754, p = 0.0003).showed opposite correlations with latency to persistent sleep and sleep efficiency after 12 weeks of lemborexant treatment (r = 0.523, p = 0.018, r = -0.516, p = 0.020, respectively). There were no significant differences in SCFAs during the treatment period. Tannerellaceae Parabacteroides Akkermansia Allisonella
CONCLUSION: Our findings suggest that prolonged lemborexant treatment in individuals with insomnia may induce notable shifts in gut microbiota composition, including a significant reduction inunderscoring the potential interaction between hypnotic use and gut microbial balance. Parabacteroides
Key numbers
p < 0.05
Increase in
Measured by Jaccard dissimilarity after 12 weeks of treatment.
p < 0.05
Increase in F/B Ratio
Significantly higher at week 12 compared to baseline.
p = 0.0001
Reduction in Specific Genera
Notably lower at week 12 compared to baseline.
Full Text
We can’t show the full text here under this license.
AF and YK are employees of Eisai Co., Ltd. KI received personal fees from Eisai, Lundbeck Japan, MSD, Otsuka, Sumitomo Pharma, Takeda, Viatris, Yoshitomi, Meiji Seika Pharma, DAIICHI SANKYO and Kyowa outside of the submitted work. NO has received research support or speaker honoraria from, or has served as a joint researcher with, or a consultant to, Otsuka Pharmaceutical Co., Ltd., Sumitomo Pharma Co., Ltd., Viatris Inc., Eisai Co., Ltd., The KAITEKI Institute, Inc., Ricoh Co., Ltd., Mitsubishi Tanabe Pharma Co.; reports personal fees/grants from Kyowa Pharmaceutical Industry, Medical Review, Eli Lilly, DAIICHI SANKYO, TSUMURA, Takeda, Mochida, Meiji Seika Pharma, EA Pharma, Viatris, Ricoh, Nippon Boehringer Ingelheim, Lundbeck Japan, Nihon Medi-Physics, Nippon Chemiphar, outside the submitted work. The other authors declare no conflicts of interest.
PubMed
Weekly Gut-Brain Axis Brief
You found one interesting study. We’ll send the next 7.
Get 7 new gut-brain axis papers each week, explained in plain English with direct links to the originals.
